Multi-institution Phase I/II Dose Escalation Study of Hypofractionated Stereotactic Body Radiation Therapy for Primary Hepatocellular Carcinoma
Despite recent advances in early detection and diagnosis, only 30-40% of patients with
hepatocellular carcinoma may benefit from radical therapies. Liver transplantation offers
the best chance for cure. Surgical resection has been the only other potentially curative
option, but the majority of patients are not candidates for resection. This reflects the
usual comorbidity of severe underlying liver disease that either precludes surgery or makes
the surgical approach extremely dangerous.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine 6 month local in-field control of this patient population
2 years from enrollment completion
Yes
Higinia Cardenes
Principal Investigator
Indiana University School of Medicine
United States: Institutional Review Board
0404-20
NCT00243841
May 2004
December 2015
Name | Location |
---|---|
Indiana University Department of Radiation Oncology | Indianapolis, Indiana 46202 |